MaxCyte shares are trading lower after the company said it sees a year-over-year decrease of 25 to 27 percent in preliminary Q3 total revenue.
Portfolio Pulse from Benzinga Newsdesk
MaxCyte announced a year-over-year decrease of 25 to 27 percent in preliminary Q3 total revenue, leading to a drop in its share price.
October 04, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
MaxCyte's shares are trading lower due to a significant decrease in its preliminary Q3 total revenue.
MaxCyte's announcement of a significant decrease in its preliminary Q3 total revenue has led to a drop in its share price. This negative financial performance is likely to impact investor confidence and could lead to further selling pressure in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100